SEC Form 4	
------------	--

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287				
Estimated average burden					
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Lloyd-Smith Malcolm				2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>NEUROCRINE BIOSCIENCES INC</u> [ NBIX ]								X (Che	elationship o eck all applic Directo	able)	g Pers	on(s) to Issu 10% Ow Other (s	ner	
(Last) (First) (Middle) 12780 EL CAMINO REAL				3. Date of Earliest Transaction (Month/Day/Year) 01/31/2022							_ 2	X below) below) Chief Regulatory Officer						
(Street) SAN DII (City)			92130 (Zip)		4. If Am	endment, Date	of Orig	ginal I	Filed	(Month/Da	ay/Ye	ear)	Line	K Form fi	led by One led by More	Repo	(Check App rting Persor One Repor	ı
		Tab	ole I - Nor	n-Deriva	ative Se	ecurities Ac	quir	red, I	Disp	osed o	of, o	r Bene	ficiall	y Owned				
Date		2. Transa Date (Month/D		2A. Deemed Execution Date if any (Month/Day/Yea	e, Transaction Dispose Code (Instr. 5)			curities Acquired (A) sed Of (D) (Instr. 3, 4			5. Amour Securitie Beneficia Owned F Reported	s ally ollowing	Form:	Direct Indirect Estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							C	ode	v	Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(1130.4)
		-				curities Acq Is, warrants								Owned	,			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution I if any (Month/Day	Date, Ti	ransaction ode (Instr.	insaction of E		6. Date Exercisable and Expiration Date (Month/Day/Year)			of S Uni Dei	Fitle and A Securities derlying rivative Se str. 3 and	ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Date Exercisable

(1)

(3)

Expiration Date

01/31/2032

(3)

Title

Common Stock

Common

Stock

1. Represents option of which 1/12th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/12th of the shares underlying the option becomes vested and
exercisable each month thereafter.

01/31/2022

01/31/2022

2. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

3. The Restricted Stock Units vests in full on the first anniversary of the date of grant.

**Remarks:** 

Stock

Option Restricted

Stock Unit

\$79.02

(2)

Explanation of Responses:

/s/ Darin Lippoldt, Attorney-in-Fact 02/02/2022

Amount or Number

of Shares

21,546

3,164

\*\* Signature of Reporting Person

\$0.00

\$0.00

21,546

3.164

Date

D

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{*}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

A

A

(A)

21,546

3.164

(D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.